In a filing, Orchestra BioMed Holdings Inc revealed its Director Aryeh Jason acquired Company’s shares for reported $2450.0 on Sep 19 ’25. In the deal valued at $2.45 per share,1,000 shares were bought. As a result of this transaction, Aryeh Jason now holds 108,482 shares worth roughly $0.26 million.
Then, Fain Eric S bought 5,760 shares, generating $15,034 in total proceeds. Upon buying the shares at $2.61, the Director now owns 71,709 shares.
Before that, Sherman Darren bought 3,000 shares. Orchestra BioMed Holdings Inc shares valued at $7,860 were divested by the insider at a price of $2.62 per share. As a result of the transaction, Sherman Darren now holds 926,837 shares, worth roughly $2.26 million.
BTIG Research downgraded its Orchestra BioMed Holdings Inc [OBIO] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. Barclays began covering OBIO with “an Overweight” recommendation on January 02, 2025. H.C. Wainwright started covering the stock on August 22, 2024. It rated OBIO as “a Buy”.
Price Performance Review of OBIO
On Friday, Orchestra BioMed Holdings Inc [NASDAQ:OBIO] saw its stock fall -2.79% to $2.44. Over the last five days, the stock has lost -5.06%. Orchestra BioMed Holdings Inc shares have fallen nearly -48.31% since the year began. Nevertheless, the stocks have fallen -39.00% over the past one year.
How much short interest is there in Orchestra BioMed Holdings Inc?
A steep rise in short interest was recorded in Orchestra BioMed Holdings Inc stocks on 2025-08-29, growing by 0.27 million shares to a total of 0.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 0.51 million shares. There was a rise of 34.57%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 25, 2024 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $15 price target.
